欧林生物(688319) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥66,871,073.79, representing a year-on-year increase of 24.91%[5] - The net profit attributable to shareholders was ¥3,853,633.15, with a net profit excluding non-recurring gains and losses of ¥2,939,010.93[5] - Basic and diluted earnings per share were both ¥0.0095[6] - Total operating revenue for Q1 2023 was CNY 66,871,073.79, an increase of 24.9% compared to CNY 53,535,183.63 in Q1 2022[17] - Net profit for Q1 2023 was CNY 2,348,538.26, a significant recovery from a net loss of CNY 6,805,222.26 in Q1 2022[18] - The total comprehensive income for the first quarter of 2023 was CNY 2,348,538.26, compared to a loss of CNY 6,805,222.26 in the same period of 2022[19] - Basic and diluted earnings per share for the first quarter of 2023 were CNY 0.0095, an improvement from a loss of CNY 0.0168 in the first quarter of 2022[19] Cash Flow - The net cash flow from operating activities was negative at -¥33,277,917.58[6] - Cash inflow from operating activities was CNY 109,853,310.29, up from CNY 74,818,965.37 in the first quarter of 2022, representing an increase of approximately 46.8%[22] - Cash outflow from operating activities totaled CNY 143,131,227.87, compared to CNY 118,118,814.99 in the same period last year, indicating a rise of about 21.1%[22] - The net cash flow from operating activities was a negative CNY 33,277,917.58, an improvement from a negative CNY 43,299,849.62 in the first quarter of 2022[22] - Cash inflow from investing activities was CNY 90,644,728.77, down from CNY 100,363,149.46 in the previous year[22] - The net cash flow from investing activities was CNY 69,535,636.33, a significant recovery from a negative CNY 59,996,452.15 in the first quarter of 2022[22] - Cash inflow from financing activities was CNY 45,000,000.00, compared to CNY 50,000,000.00 in the first quarter of 2022[23] - The net cash flow from financing activities was a negative CNY 6,005,425.90, contrasting with a positive CNY 49,170,599.36 in the same period last year[23] - The ending cash and cash equivalents balance was CNY 291,362,822.86, an increase from CNY 185,144,001.68 at the end of the first quarter of 2022[23] Research and Development - The total R&D investment amounted to ¥25,233,561.99, which is 37.73% of the operating revenue, an increase of 7.15 percentage points compared to the previous year[6] - Research and development expenses for Q1 2023 amounted to CNY 18,648,503.13, compared to CNY 16,373,473.10 in Q1 2022, indicating a 13.9% increase[17] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,402,265,690.70, a decrease of 5.18% from the end of the previous year[6] - The company's total assets as of Q1 2023 were CNY 1,402,265,690.70, a decrease from CNY 1,478,871,193.65 at the end of the previous period[16] - Total liabilities for Q1 2023 were CNY 509,589,233.11, down from CNY 587,022,458.86 in the previous period, representing a reduction of 13.2%[15] - The company's cash and cash equivalents decreased to CNY 847,505,898.50 from CNY 935,894,525.77, a decline of 9.4%[16] - The company reported an increase in accounts receivable to CNY 453,260,960.60 from CNY 491,171,654.30, a decrease of 7.7%[16] - The company’s total equity increased slightly to CNY 892,676,457.59 from CNY 891,848,734.79, reflecting a marginal growth[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,203[10] - The largest shareholder, Chongqing Wushan Biological Technology Co., Ltd., holds 72,394,330 shares, accounting for 17.86% of the total shares[10] Future Outlook - The company plans to continue investing in new product development and market expansion strategies to drive future growth[18]